Partners Dan Altman and David Schmidt, Ph.D., gave an informative presentation focused on strategic considerations for drafting and prosecuting patent claims directed to life sciences-related inventions, before the United States Patent and Trademark Office. The presentation was summarized in Japanese by IP Strategist, Kenny Masaki.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
Partners Dan Altman, David Schmidt, Ph.D. and Jessica Achtsam gave an informative presentation on strategic considerations for claim drafting life sciences inventions. The partners provided insights related to effective and efficient patent prosecution for life sciences-related inventions.
Patents on Software and Business Methods: Have the Rules Changed?Karl Larson
The standard for patentable subject matter under Bilski is a “machine-or-transformation test,” which restricts patenting to inventions that are either tied to a particular machine or apparatus, or that transform a particular article into a different state or thing.
Presentation on Patent DNA by Nitin Nair, Brain League IP Services Now BananaIPBananaIP Counsels
Presentation on Patent DNA by Nitin Nair, Brain League IP Services Now BananaIP
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
Case studies presentation_Patent Research AESAN PATEL
Infringement: A term which is very common in patent research and law forms. i.e. the action of breaking the terms of a law, agreement, etc.; violation.
Partners Dan Altman and David Schmidt, Ph.D., gave an informative presentation focused on strategic considerations for drafting and prosecuting patent claims directed to life sciences-related inventions, before the United States Patent and Trademark Office. The presentation was summarized in Japanese by IP Strategist, Kenny Masaki.
The Federal Circuit Review is a monthly newsletter featuring the latest case summaries handed down from the U.S. Court of Appeals for the Federal Circuit.
Partners Dan Altman, David Schmidt, Ph.D. and Jessica Achtsam gave an informative presentation on strategic considerations for claim drafting life sciences inventions. The partners provided insights related to effective and efficient patent prosecution for life sciences-related inventions.
Patents on Software and Business Methods: Have the Rules Changed?Karl Larson
The standard for patentable subject matter under Bilski is a “machine-or-transformation test,” which restricts patenting to inventions that are either tied to a particular machine or apparatus, or that transform a particular article into a different state or thing.
Presentation on Patent DNA by Nitin Nair, Brain League IP Services Now BananaIPBananaIP Counsels
Presentation on Patent DNA by Nitin Nair, Brain League IP Services Now BananaIP
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
Case studies presentation_Patent Research AESAN PATEL
Infringement: A term which is very common in patent research and law forms. i.e. the action of breaking the terms of a law, agreement, etc.; violation.
Think your innovation is sufficiently enabled to secure, defend, and assert your patent rights? If it’s a biological, chemical, or emerging technology invention then you might want to think again. In today’s episode we’re looking into how to get more predictable results from the unpredictable arts.
Some technologies, like those rooted in physics and mechanics, are considered “predictable” by the US Patent Office, while others, like biological and chemical technologies, are generally considered “unpredictable.” It follows that the amount of disclosure required to enable an invention is related to the predictability of the technology, and so-called unpredictable arts require more description to teach a reader how to “make and use” the technology. Similarly, emerging technologies, being less well known, also require more disclosure to be fully enabled.
In this month’s episode, David Jackrel, President of Jackrel Consulting, leads a discussion along with our all star patent panel, exploring enablement for the unpredictable arts and emerging technologies. The panel discusses peculiarities of patenting unpredictable art and emerging technologies, with a focus on modern case law and statutes to arrive at a set of best practices for getting more predictable results when patenting these technologies.
Dave is also joined today by our always exceptional group of IP experts including:
⦿ Dr. Ashley Sloat, President and Director of Patent Strategy at Aurora
⦿ Kristen Hansen, Patent Strategist at Aurora
⦿ Shelley Couturier, Patent Strategist and Search Specialist
Before joining the group, as we often do, we’d like to provide a short primer on some key concepts in this episode for those newer to the world of patenting. This primer covers:
⦿ Section 112
⦿ What is the MPEP?
⦿ Specification vs. Claims
⦿ Genus vs. Species Claims
⦿ Markush Groups
We’re leading off Season 3 with a close look at a Supreme Court patent case that could have profound impacts on the invention enablement problems we covered heavily in Season 2. SCOTUS is set to hear opening arguments in Amgen v Sanofi on March 27th. For the first time in over 75 years, the Supreme Court is evaluating the meaning and scope of the enablement requirement. For those who’ve been following along, you’ll know that this has become one of the bigger issues plaguing patenting and especially so in the life sciences.
Dr. Ashley Sloat, President and Director of Patent Strategy at Aurora, leads our discussion today along with our all star patent panel, exploring the scientific background around antibodies necessary to understand the claims, a brief case history of Amgen v Sanofi, an overview of the enablement factors and tests that have been historically applied in courts and how they might apply to this case, and a discussion around open questions and the potential unintended consequences of the Supreme Court only taking up one-half of the two-sided enablement coin. This ends up being a really great, spirited conversation with panel members coming down strongly on both sides of the case with very compelling arguments – really highlighting the complexities and fundamental issues the court will have to face.
Ashley is joined today by our always exceptional group of IP experts including:
⦿ David Cohen, Principal at Cohen Sciences
⦿ Kristen Hansen, Patent Strategist at Aurora
⦿ David Jackrel, President of Jackrel Consulting
⦿ Ty Davis, Patent Strategy Associate at Aurora
Meeting the Specs: Precision in Patent SpecificationsKirby Drake
This presentation addresses common pitfalls in patent specification preparation and also provides insight on recent USPTO guidance as well as case law guidance.
Are United States' Courts Adopting an Essential Elements Test for Patent Vali...David Thibodeau
A review of decisions by the Court of Appeals for the Federal Circuit relating to the description requirement of 35 USC 112. Recent cases such as ICU Medical and Automotive Technologies v. BMW are discussed.
Life science patents have grown increasingly vulnerable to rejection and invalidation due to subject matter eligibility and enablement interpretations. The implications are staggering with over 80% of abandoned life science applications having a final rejection stating that the innovation did not include patentable subject matter. In this talk, we’ll explore how to avoid these rejections, understand the implications for new drugs, and provide practical tips for creating robust life science patents.
Patent: A presentation on "Patent Drafting" by Ms. Vinita Radhakrishnan - Ban...BananaIP Counsels
Patent: A presentation on "Patent Drafting" by Ms. Vinita Radhakrishnan - BananaIP
BananaIP Counsels, formerly Brain League IP Services, founded in 2004 at the Indian Institute of Management (IIM) Bangalore’s incubation center (NSRCEL), is recognized as an IP/Patent trailblazer in India. The firm’s mission is to help clients maximize business value from their Intellectual Property (IP)/Patents, and gain competitive advantage in the market place. In its evolution from Brain League, BananaIP carries forward the firm’s core values – Merger of Technology,Management and Law, Swift Adaptation to changes in competitive environment, and business driven approach to Intellectual Property (IP)/Patent Services.
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
CAFC Chronicles: Costly Tales of Claim Construction FailsAurora Consulting
The difference between getting claim construction right and getting it wrong is the difference between a valid patent and an invalid patent – and the difference between millions of dollars awarded from infringement decisions vs. ending up with a worthless piece of paper.
In this month’s episode, Dr. David Jackrel, President of Jackrel Consulting, leads a discussion into three real-world applications for patent claim construction, as tested and decided upon by the United States Court of Appeals for the Federal Circuit. This is the highest court in the land under the Supreme Court for handling intellectual property disputes – and establishes much of the legal precedent the patent world has to go on … for better and for worse. The panel dissects the claims for each case, discusses the court’s analysis, and provides tips and strategies for more effective claim drafting in light of the strengths and weaknesses of the litigated patents.
Dave is joined today by our always exceptional group, including:
⦿ Dr. Ashley Sloat, President and Director of Patent Strategy at Aurora
⦿ Kristen Hansen, Patent Strategy Specialist at Aurora
⦿ Ty Davis, Patent Strategy Associate at Aurora
Listen here: https://patentlystrategic.buzzsprout.com/1734511/14991984-cafc-chronicles-costly-tales-of-claim-construction-fails
Patentability of Computer Related Inventions (CRIs) in IndiaArun Narasani
The patentability requirements for Computer Related Inventions (CRIs) under Indian Patent Law have been unclear. It is generally understood that a CRI must demonstrate “technical effect” and the relevant claims must have “machine limitation”, in addition to the basic patentability requirements of novelty, inventive step, and industrial applicability.
However, the phrase “technical effect” has not been defined properly. Further, the legal basis for technical effect requirement has not been clarified.
In this session, we will take a close look at the guidelines for examination of CRIs published recently by the Indian Patent Office to gain some insights regarding the "technical effect" requirement.
Take Aways:
- Understand evolution of patent law with reference protection of CRIs
- Understand “technical effect” requirement and legal basis for the requirement
- Understand patentability of CRIs in India through examples
Think your innovation is sufficiently enabled to secure, defend, and assert your patent rights? If it’s a biological, chemical, or emerging technology invention then you might want to think again. In today’s episode we’re looking into how to get more predictable results from the unpredictable arts.
Some technologies, like those rooted in physics and mechanics, are considered “predictable” by the US Patent Office, while others, like biological and chemical technologies, are generally considered “unpredictable.” It follows that the amount of disclosure required to enable an invention is related to the predictability of the technology, and so-called unpredictable arts require more description to teach a reader how to “make and use” the technology. Similarly, emerging technologies, being less well known, also require more disclosure to be fully enabled.
In this month’s episode, David Jackrel, President of Jackrel Consulting, leads a discussion along with our all star patent panel, exploring enablement for the unpredictable arts and emerging technologies. The panel discusses peculiarities of patenting unpredictable art and emerging technologies, with a focus on modern case law and statutes to arrive at a set of best practices for getting more predictable results when patenting these technologies.
Dave is also joined today by our always exceptional group of IP experts including:
⦿ Dr. Ashley Sloat, President and Director of Patent Strategy at Aurora
⦿ Kristen Hansen, Patent Strategist at Aurora
⦿ Shelley Couturier, Patent Strategist and Search Specialist
Before joining the group, as we often do, we’d like to provide a short primer on some key concepts in this episode for those newer to the world of patenting. This primer covers:
⦿ Section 112
⦿ What is the MPEP?
⦿ Specification vs. Claims
⦿ Genus vs. Species Claims
⦿ Markush Groups
We’re leading off Season 3 with a close look at a Supreme Court patent case that could have profound impacts on the invention enablement problems we covered heavily in Season 2. SCOTUS is set to hear opening arguments in Amgen v Sanofi on March 27th. For the first time in over 75 years, the Supreme Court is evaluating the meaning and scope of the enablement requirement. For those who’ve been following along, you’ll know that this has become one of the bigger issues plaguing patenting and especially so in the life sciences.
Dr. Ashley Sloat, President and Director of Patent Strategy at Aurora, leads our discussion today along with our all star patent panel, exploring the scientific background around antibodies necessary to understand the claims, a brief case history of Amgen v Sanofi, an overview of the enablement factors and tests that have been historically applied in courts and how they might apply to this case, and a discussion around open questions and the potential unintended consequences of the Supreme Court only taking up one-half of the two-sided enablement coin. This ends up being a really great, spirited conversation with panel members coming down strongly on both sides of the case with very compelling arguments – really highlighting the complexities and fundamental issues the court will have to face.
Ashley is joined today by our always exceptional group of IP experts including:
⦿ David Cohen, Principal at Cohen Sciences
⦿ Kristen Hansen, Patent Strategist at Aurora
⦿ David Jackrel, President of Jackrel Consulting
⦿ Ty Davis, Patent Strategy Associate at Aurora
Meeting the Specs: Precision in Patent SpecificationsKirby Drake
This presentation addresses common pitfalls in patent specification preparation and also provides insight on recent USPTO guidance as well as case law guidance.
Are United States' Courts Adopting an Essential Elements Test for Patent Vali...David Thibodeau
A review of decisions by the Court of Appeals for the Federal Circuit relating to the description requirement of 35 USC 112. Recent cases such as ICU Medical and Automotive Technologies v. BMW are discussed.
Life science patents have grown increasingly vulnerable to rejection and invalidation due to subject matter eligibility and enablement interpretations. The implications are staggering with over 80% of abandoned life science applications having a final rejection stating that the innovation did not include patentable subject matter. In this talk, we’ll explore how to avoid these rejections, understand the implications for new drugs, and provide practical tips for creating robust life science patents.
Patent: A presentation on "Patent Drafting" by Ms. Vinita Radhakrishnan - Ban...BananaIP Counsels
Patent: A presentation on "Patent Drafting" by Ms. Vinita Radhakrishnan - BananaIP
BananaIP Counsels, formerly Brain League IP Services, founded in 2004 at the Indian Institute of Management (IIM) Bangalore’s incubation center (NSRCEL), is recognized as an IP/Patent trailblazer in India. The firm’s mission is to help clients maximize business value from their Intellectual Property (IP)/Patents, and gain competitive advantage in the market place. In its evolution from Brain League, BananaIP carries forward the firm’s core values – Merger of Technology,Management and Law, Swift Adaptation to changes in competitive environment, and business driven approach to Intellectual Property (IP)/Patent Services.
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
CAFC Chronicles: Costly Tales of Claim Construction FailsAurora Consulting
The difference between getting claim construction right and getting it wrong is the difference between a valid patent and an invalid patent – and the difference between millions of dollars awarded from infringement decisions vs. ending up with a worthless piece of paper.
In this month’s episode, Dr. David Jackrel, President of Jackrel Consulting, leads a discussion into three real-world applications for patent claim construction, as tested and decided upon by the United States Court of Appeals for the Federal Circuit. This is the highest court in the land under the Supreme Court for handling intellectual property disputes – and establishes much of the legal precedent the patent world has to go on … for better and for worse. The panel dissects the claims for each case, discusses the court’s analysis, and provides tips and strategies for more effective claim drafting in light of the strengths and weaknesses of the litigated patents.
Dave is joined today by our always exceptional group, including:
⦿ Dr. Ashley Sloat, President and Director of Patent Strategy at Aurora
⦿ Kristen Hansen, Patent Strategy Specialist at Aurora
⦿ Ty Davis, Patent Strategy Associate at Aurora
Listen here: https://patentlystrategic.buzzsprout.com/1734511/14991984-cafc-chronicles-costly-tales-of-claim-construction-fails
Patentability of Computer Related Inventions (CRIs) in IndiaArun Narasani
The patentability requirements for Computer Related Inventions (CRIs) under Indian Patent Law have been unclear. It is generally understood that a CRI must demonstrate “technical effect” and the relevant claims must have “machine limitation”, in addition to the basic patentability requirements of novelty, inventive step, and industrial applicability.
However, the phrase “technical effect” has not been defined properly. Further, the legal basis for technical effect requirement has not been clarified.
In this session, we will take a close look at the guidelines for examination of CRIs published recently by the Indian Patent Office to gain some insights regarding the "technical effect" requirement.
Take Aways:
- Understand evolution of patent law with reference protection of CRIs
- Understand “technical effect” requirement and legal basis for the requirement
- Understand patentability of CRIs in India through examples
Developing IP Portfolio, By Arun NarasaniArun Narasani
Developing IP Portfolio involves developing a framework using a set of discrete techniques and tools. This presentation provides a framework and talks about the need for IP Policy, IP Process, analysis tools, sustainable innovation process, portfolio management. The presentation also introduces TRIZ and drives the fact that innovation can be institutionalized.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...NelTorrente
In this research, it concludes that while the readiness of teachers in Caloocan City to implement the MATATAG Curriculum is generally positive, targeted efforts in professional development, resource distribution, support networks, and comprehensive preparation can address the existing gaps and ensure successful curriculum implementation.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
The simplified electron and muon model, Oscillating Spacetime: The Foundation...RitikBhardwaj56
Discover the Simplified Electron and Muon Model: A New Wave-Based Approach to Understanding Particles delves into a groundbreaking theory that presents electrons and muons as rotating soliton waves within oscillating spacetime. Geared towards students, researchers, and science buffs, this book breaks down complex ideas into simple explanations. It covers topics such as electron waves, temporal dynamics, and the implications of this model on particle physics. With clear illustrations and easy-to-follow explanations, readers will gain a new outlook on the universe's fundamental nature.
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
Safalta Digital marketing institute in Noida, provide complete applications that encompass a huge range of virtual advertising and marketing additives, which includes search engine optimization, virtual communication advertising, pay-per-click on marketing, content material advertising, internet analytics, and greater. These university courses are designed for students who possess a comprehensive understanding of virtual marketing strategies and attributes.Safalta Digital Marketing Institute in Noida is a first choice for young individuals or students who are looking to start their careers in the field of digital advertising. The institute gives specialized courses designed and certification.
for beginners, providing thorough training in areas such as SEO, digital communication marketing, and PPC training in Noida. After finishing the program, students receive the certifications recognised by top different universitie, setting a strong foundation for a successful career in digital marketing.
Normal Labour/ Stages of Labour/ Mechanism of LabourWasim Ak
Normal labor is also termed spontaneous labor, defined as the natural physiological process through which the fetus, placenta, and membranes are expelled from the uterus through the birth canal at term (37 to 42 weeks
A workshop hosted by the South African Journal of Science aimed at postgraduate students and early career researchers with little or no experience in writing and publishing journal articles.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
3. Contents of the specification – US
Title of the invention
Cross-reference to related applications
Statement regarding federally sponsored research or development
The names of the parties to a joint research agreement
Reference to a "Sequence Listing"
Background of the invention
(1) Field of the invention
(2) Description of related art including information disclosed under IDS
Brief summary of the invention
Brief description of the several views of the drawing
Detailed description of the invention
Claim(s) (commencing on a separate sheet)
Abstract of the Disclosure (commencing on a separate sheet)
Sequence Listing
ipMetrix
4. Contents of the specification – India
Title
Field of the Invention and use of Invention
Prior Art and problem to be solved
Objects of the Invention
Summary of the Invention
Detailed Description of Invention
Drawings
Abstract
Claims
ipMetrix
5. Background requirements – US
“The specification must set forth the precise
invention for which a patent is solicited, in
such manner as to distinguish it from other
inventions and from what is old.” (37 CFR
1.71)
But, no real guideline on what should be or
should not be part of the background section
ipMetrix
6. Background requirements – India
“This part should indicate the status of the technology in the
field of invention with reference to developments in the field,
patents and pending patent applications in the specific art.”
“When the invention relates to an improvement on an existing
product or process, a short statement of the closest prior art
known to the applicant shall also be given.”
“However, the description should fully and particularly
describe the invention, by clearly distinguishing it from such a
closest prior art, known to the applicant.”
ipMetrix
7. Background requirements – India
Objects of the invention
“The purpose of this part is to clearly bring out
the necessity of the invention. It shall clearly
mention the technical problems associated with
the existing technology and the solution for that,
bringing out the obvious differences between the
claimed invention and the prior art.”
ipMetrix
9. KSR v. Teleflex
Facts
Teleflex, Inc. sued KSR International, claiming that one of
KSR's products infringed Teleflex's patent[1] on connecting
an adjustable vehicle control pedal to an electronic
throttle control. KSR argued that the combination of the
two elements was obvious, and the claim was therefore
not patentable.
The district court ruled in favor of KSR
The Court of Appeals for the Federal Circuit reversed the
decision.
The Supreme Court reversed the judgement unanimously
ipMetrix
10. KSR v. Teleflex
Impact on Background
“The combination of familiar elements according to known
methods is likely to be obvious when it does no more than
yield predictable results.”
“In determining whether the subject matter of a patent
claim is obvious, neither the particular motivation nor the
avowed purpose of the patentee controls. What matters is
the objective reach of the claim. If the claim extends to
what is obvious, it is invalid under § 103. One of the ways
in which a patent's subject matter can be proved obvious is
by noting that there existed at the time of invention a
known problem for which there was an obvious solution
encompassed by the patent's claims.”
ipMetrix
11. Rule 1
Keep description of prior art simple
Avoid characterizing any specific prior art
When talking about prior art in general, avoid
suggesting that the invention is based on known
elements and known functions of such elements
When not possible, need to demonstrate
unpredictability of the result in the specification
Avoid suggesting that the problem is well known
in the prior art
ipMetrix
12. In re O’Farrell
Facts
Examiner rejects the claims for “A method for
producing a predetermined protein in a stable
form in a transformed host species of bacteria”
BPAI affirms patent examiner's final rejection of
patent application entitled "Method and Hybrid
Vector for Regulating Translation of
Heterologous DNA in Bacteria.“
The Court of Appeals for the Federal Circuit
affirms the decision.
ipMetrix
13. In re O’Farrell
Impact on Background
Obvious-to-try does not mean obviousness
Explores the circumstances where it is obvious-to-try but the
invention is non-obvious
“In some cases, what would have been "obvious to try" would
have been to vary all parameters or try each of numerous
possible choices until one possibly arrived at a successful result,
where the prior art gave either no indication of which
parameters were critical or no direction as to which of many
possible choices is likely to be successful.”
“In others, what was "obvious to try" was to explore a new
technology or general approach that seemed to be a promising
field of experimentation, where the prior art gave only general
guidance as to the particular form of the claimed invention or
how to achieve it.”
ipMetrix
14. Rule 2
Do not suggest that the invention is obviousto-try
Avoid characterizing prior arts that provide
guidance in the direction of invention
For improvement patents, ensure that one of the
following is established
Invention involves choosing a particular option out
of a large set of options that was not suggested by
the prior art; and/or
Improvement involves exploration of new
technology that was not suggested by the prior art
ipMetrix
15. Pfizer v. Apotex
Facts
Norvasc is Pfizer's patented blockbuster drug for
treating hypertension and angina
The trial court upholds Pfizer's patent and issues
an injunction stopping Apotex from making a
generic version
The Court of Appeals for the Federal Circuit
invalidates Pfizer's patent, finding it obvious.
ipMetrix
16. Pfizer v. Apotex
Impact on Background
“.. prior art provided not only the means of
creating acid addition salts but also predicted the
results, which Pfizer merely had to verify through
routine testing.”
ipMetrix
17. Rule 3
Do not suggest that the invention is based on
routine experimentation based on known
elements and known functions (conditions)
Avoid characterization of specific prior art that
suggests the elements or predicts the results
even in general
When not possible, need to establish
unpredictability of results
Please note that obviousness does not require
absolute predictability of success. (In re O’Farrell)
ipMetrix
18. Some pet peeves
Lack of flow of logic from one paragraph to
another
Informal language
Inappropriate sentence formation
Inappropriate use of articles
ipMetrix
19. Example
Invention:
Method of organizing data in an enterprise for
ease of access
Preferred embodiment uses Internet as a means
Background
Starts with how Internet has impacted lives
How organizations cannot access data without
Internet
Establishing a need for easy access of data using
Internet
ipMetrix
20. The logging server was
never introduced before
Example
There is no specific data
path that you can refer to
“Also, rate limiting of the network traffic
occurs at the debug logging server level. The
logging server has to rate-limit the logs
generated by the data path, which will
continuously keep on generating logs, hence
adversely affecting the performance of the
router/switch.”
Informal language
Complex sentence and no
clear articulation
ipMetrix
21. Summary
Avoid content in background that hints that the
invention at hand
is based on
Known functions of known elements leading to
predictable results
Or is based on
Routine finding/experimentation
Or is
Obvious-to-try
Or
Solves a known problem with generally known elements
in the prior art
ipMetrix
22. Summary
Understand the problem that the invention is trying
to solve
Not enough to understand the preferred embodiment
Avoid talking about specific embodiment details in
background; focus on the larger problem
Follow basic writing rules
Plan for the flow of logic before writing
Ensure that there is flow of logic from one para to another
Follow basic grammar rules and usage of proper articles
ipMetrix
23. Conclusion
Keep background very simple
Establish need for invention in a generic
sense without characterizing any specific
prior art
ipMetrix